MedTrace Logo

Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial

NCT00370851 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2009-11-25

No results posted yet for this study

Summary

In this study we intend to evaluate the outcome of intravitreal avastin on improving the visual acuity and macular edema and late complications of BRVO like NVD and NVE

Conditions

  • Retinal Disease

Interventions

DRUG

Avastin (Bevacizumab)

Intravitreal injection of 125 mg Avastin

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Siamak Moradian, MD · Ophthalmic Research Center of Shaheed Beheshti Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-02-29
Completion
2008-06-30

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370851 on ClinicalTrials.gov